Model List of Essential Medicines

Azithromycin

Section	Indications
Watch group antibiotics ◦ Oral > Liquid: 200 mg per 5 mL (anhydrous) powder for oral liquid ◦ Oral > Solid > dosage form: 250 mg (anhydrous); 500 mg (anhydrous)	**First choice** Cholera Cholera [children] Paratyphoid fever Chlamydia trachomatis Typhoid fever Yaws Trachoma co-prescribed with ceftriaxone Gonococcal infection **Second choice** Infectious gastroenteritis or colitis without specification of infectious agent co-prescribed with cefixime Gonococcal infection

Cefepime

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > unspecified: 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection; 2 g in vial (as hydrochloride) powder for injection	Other specified bacterial diseases

Cefixime

Section	Indications
Watch group antibiotics ◦ Oral > Liquid: 100 mg per 5 mL powder for oral liquid ◦ Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)	**Second choice** Infectious gastroenteritis or colitis without specification of infectious agent co-prescribed with azithromycin Gonococcal infection

Cefotaxime

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt) ◦ Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt)	**First choice** Acute pyelonephritis (severe) Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Bacterial pneumonia (Community-acquired pneumonia - severe) Other specified pneumonia (Hospital-acquired pneumonia) Bacterial meningitis co-prescribed with amikacin Inflammatory or other diseases of prostate (severe) co-prescribed with metronidazole Peritoneal abscess (mild-moderate) co-prescribed with metronidazole Peritoneal abscess (severe) co-prescribed with metronidazole Peritonitis (mild-moderate) co-prescribed with metronidazole Peritonitis (severe) **Second choice** Acute pyelonephritis (mild to moderate) Sepsis without septic shock Bacterial infection of joint Inflammatory or other diseases of prostate (mild to moderate) Osteomyelitis or osteitis **Other indications** Bacterial infection of unspecified site

Ceftazidime

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection	**First choice** Endophthalmitis **Other indications** Pseudomonas aeruginosa resistant to other antibiotic

Ceftriaxone

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt) ◦ Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt) ◦ Parenteral > Locoregional injections > Intravitreal: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt) ◦ Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial ◦ Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)	**First choice** Other specified pneumonia (Hospital-acquired pneumonia) Acute pyelonephritis (severe) Paratyphoid fever Typhoid fever Endophthalmitis Bacterial pneumonia (Community-acquired pneumonia - severe) Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Bacterial meningitis co-prescribed with amikacin Inflammatory or other diseases of prostate (severe) co-prescribed with azithromycin Gonococcal infection co-prescribed with metronidazole Necrotising fasciitis co-prescribed with metronidazole Peritoneal abscess (mild-moderate) co-prescribed with metronidazole Peritoneal abscess (severe) co-prescribed with metronidazole Peritonitis (mild-moderate) co-prescribed with metronidazole

Peritonitis (severe)

Second choice

Acute pyelonephritis (mild to moderate)

Bacterial infection of joint

Sepsis without septic shock

Infectious gastroenteritis or colitis without specification of infectious agent

Inflammatory or other diseases of prostate (mild to moderate)

Osteomyelitis or osteitis

Other indications

Bacterial infection of unspecified site

Cefuroxime

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection	**Second choice** Other specified prophylactic measures

Ciprofloxacin

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > IV: 2 mg per mL (as hyclate) ◦ Oral > Liquid: 250 mg per 5 mL (anhydrous) ◦ Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride); 100 mg (as hydrochloride) ◦ Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride) ◦ Oral > Solid: 250 mg (as hydrochloride)	**First choice** Acute pyelonephritis (mild to moderate) Paratyphoid fever Typhoid fever Infectious gastroenteritis or colitis without specification of infectious agent Neutropaenia (low-risk) Inflammatory or other diseases of prostate (mild to moderate) **Second choice** Cholera Cholera [children] co-prescribed with metronidazole Peritoneal abscess (mild-moderate) co-prescribed with metronidazole Peritonitis (mild-moderate) **Other indications** Bacterial infection of unspecified site

Clarithromycin

Section	Indications
Watch group antibiotics ◦ Oral > Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid ◦ Parenteral > General injections > unspecified: 500 mg in vial powder for injection ◦ Oral > Solid > dosage form: 500 mg; 250 mg ◦ Oral > Solid > dosage form: 500 mg	**First choice** co-prescribed with cefotaxime Bacterial pneumonia (Community-acquired pneumonia - severe) co-prescribed with ceftriaxone Bacterial pneumonia (Community-acquired pneumonia - severe) **Second choice** Acute pharyngitis co-prescribed with amoxicillin + clavulanic acid Bacterial pneumonia (Community-acquired pneumonia - severe) **Other indications** Helicobacter pylori associated gastric ulcer

Delafloxacin

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > IV: 300 mg lyophilized powder for injection ◦ Oral > Solid: 450 mg	Methicillin resistant Staphylococcus aureus

Erythromycin

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > IV: 500 mg in vial powder for injection (as lactobionate) ◦ Oral > Liquid: 125 mg per 5 mL (as stearate or ethylsuccinate) ◦ Oral > Solid: 250 mg (as stearate or ethylsuccinate)	**Second choice** Therapeutic equivalent to clarithromycin for Acute pharyngitis **Other indications** Bacterial infection of unspecified site

Flomoxef

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > IV: 0.5 g in vial powder for injection; 1 g in vial powder for injection	Other specified other antibiotic resistant Enterobacterales

Fourth generation cephalosporins

Section	Indications
Watch group antibiotics ◦ .	Other specified bacterial diseases

Imipenem + cilastatin

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection	**Second choice** Therapeutic equivalent to meropenem for Peritoneal abscess (severe) Therapeutic equivalent to meropenem for Neutropaenia (high-risk) Therapeutic equivalent to meropenem for Peritonitis (severe) **Other indications** Pseudomonas aeruginosa resistant to other antibiotic Antibiotic resistant Acinetobacter baumannii

Meropenem

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection	**Second choice** Neonatal meningitis Peritoneal abscess (severe) Neutropaenia (high-risk) Peritonitis (severe)

Piperacillin + tazobactam

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection	**First choice** Other specified pneumonia (Hospital-acquired pneumonia) Neutropaenia (high-risk) Peritoneal abscess (severe) Peritonitis (severe) co-prescribed with clindamycin Necrotising fasciitis

Vancomycin

Section	Indications
Watch group antibiotics ◦ Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection ◦ Oral > Solid > capsule: 125 mg (as hydrochloride); 250 mg (as hydrochloride) ◦ Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection ◦ Parenteral > Locoregional injections > Intravitreal: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection	**First choice** Necrotising fasciitis co-prescribed with ceftazidime Endophthalmitis co-prescribed with ceftriaxone Endophthalmitis **Second choice** Intestinal infections due to Clostridioides difficile Neutropaenia (high-risk) **Other indications** Methicillin resistant Staphylococcus aureus